Increased Iron (III) and Total Iron Content in Post Mortem Substantia Nigra of Parkinsonian Brain

Overview

Journal J Neural Transm

Specialties Neurology
Physiology

Date 1988 Jan 1

PMID 3210014

Citations 195

Authors

E Sofic

P Riederer

H Heinsen

H Beckmann

G P Reynolds

G Hebenstreit

M B Youdim

Affiliations

Soon will be listed here.

Abstract

Significant differences in the content of iron (III) and total iron were found in post mortem substantia nigra of Parkinson's disease. There was an increase of 176% in the levels of total iron and 225% of iron (III) in the substantia nigra of the parkinsonian patients compared to age matched controls. In the cortex (Brodmann area 21), hippocampus, putamen, and globus pallidus there was no significant difference in the levels of iron (III) and total iron. Thus the changes in total iron, iron (III) and the iron (II)/iron (III) ratio in the parkinsonian substantia nigra are likely to be involved in the pathophysiology and treatment of this disorder.

Citing Articles

Longitudinal Changes of Quantitative Brain Tissue Properties Induced by Balance Training.

Aye N, Lehmann N, Kaufmann J, Heinze H, Duzel E, Ziegler G Hum Brain Mapp. 2025; 46(4):e70128.

PMID: 40017039 PMC: 11868441. DOI: 10.1002/hbm.70128.

Ferric Ammonium Citrate Reduces Claudin-5 Abundance and Function in Primary Mouse Brain Endothelial Cells.

Runwal P, Pyun J, Newman S, Mawal C, Bush A, Koehn L Pharm Res. 2025; 42(2):319-334.

PMID: 39939558 PMC: 11880181. DOI: 10.1007/s11095-025-03826-2.

Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases.

Chen L, Shen Q, Liu Y, Zhang Y, Sun L, Ma X Signal Transduct Target Ther. 2025; 10(1):31.

PMID: 39894843 PMC: 11788444. DOI: 10.1038/s41392-024-02071-0.

Ferroptosis in the Substantia Nigra Pars Compacta of Mice: Triggering Role of Ultrafine Diesel Exhaust Particles and Mitigation by α-Lipoic Acid.

Kim J, Kim A, Kim J, Gil Y, Kim Y, Shin D Neurochem Res. 2024; 50(1):37.

PMID: 39601947 DOI: 10.1007/s11064-024-04278-7.

Postencephalitic Parkinsonism: Unique Pathological and Clinical Features-Preliminary Data.

Strobel S, Sian-Hulsmann J, Tappe D, Jellinger K, Riederer P, Monoranu C Cells. 2024; 13(18.

PMID: 39329695 PMC: 11430219. DOI: 10.3390/cells13181511.

References

Nagatsu T, Kato T, Numata Y, Ikuta K, Sano M . Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain. Clin Chim Acta. 1977; 75(2):221-32. DOI: 10.1016/0009-8981(77)90193-0. View

EARLE K . Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol. 1968; 27(1):1-14. DOI: 10.1097/00005072-196801000-00001. View

Drayer B, Olanow W, Burger P, Johnson G, Herfkens R, Riederer S . Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology. 1986; 159(2):493-8. DOI: 10.1148/radiology.159.2.3961182. View

Riederer P, Sofic E, Rausch W, Schmidt B, Reynolds G, Jellinger K . Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 1989; 52(2):515-20. DOI: 10.1111/j.1471-4159.1989.tb09150.x. View

Nagatsu T, Yamaguchi T, Kato T, Sugimoto T, Matsuura S, Akino M . Biopterin in human brain and urine from controls and parkinsonian patients: application of a new radioimmunoassay. Clin Chim Acta. 1981; 109(3):305-11. DOI: 10.1016/0009-8981(81)90316-8. View

Birkmayer W, Birkmayer J . Iron, a new aid in the treatment of Parkinson patients. J Neural Transm. 1986; 67(3-4):287-92. DOI: 10.1007/BF01243354. View

Riederer P, Rausch W, Schmidt B, Kruzik P, Konradi C, Sofic E . Biochemical fundamentals of Parkinson's disease. Mt Sinai J Med. 1988; 55(1):21-8. View

Rutledge J, Hilal S, Silver A, Defendini R, Fahn S . Study of movement disorders and brain iron by MR. AJR Am J Roentgenol. 1987; 149(2):365-79. DOI: 10.2214/ajr.149.2.365. View

Dexter D, WELLS F, Agid F, Agid Y, Lees A, Jenner P . Increased nigral iron content in postmortem parkinsonian brain. Lancet. 1987; 2(8569):1219-20. DOI: 10.1016/s0140-6736(87)91361-4. View

10.

Riederer P, Rausch W, Birkmayer W, Jellinger K, Seemann D . CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies. J Neural Transm Suppl. 1978; (14):121-31. View

11.

ULE G, Volkl A, Berlet H . [Trace elements in human brain. II. Copper, zinc, calcium and magnesium of 13 brain areas compared to iron during the 4th to 8th life decade (author's transl)]. Z Neurol. 1974; 206(2):117-28. View

12.

Youdim M . Iron in the brain: implications for Parkinson's and Alzheimer's diseases. Mt Sinai J Med. 1988; 55(1):97-101. View

13.

Rausch W, Hirata Y, Nagatsu T, Riederer P, Jellinger K . Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J Neurochem. 1988; 50(1):202-8. DOI: 10.1111/j.1471-4159.1988.tb13250.x. View

14.

Ben-Shachar D, Ashkenazi R, Youdim M . Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats. Int J Dev Neurosci. 1986; 4(1):81-8. DOI: 10.1016/0736-5748(86)90019-5. View

15.

Ikeda M, Levitt M, UDENFRIEND S . HYDROXYLATION OF PHENYLALANINE BY PURIFIED PREPARATIONS OF ADRENAL AND BRAIN TYROSINE HYDROXYLASE. Biochem Biophys Res Commun. 1965; 18:482-8. DOI: 10.1016/0006-291x(65)90778-3. View

16.

Greiner A, Chan S, NICOLSON G . Human brain contents of calcium, copper, magnesium, and zinc in some neurological pathologies. Clin Chim Acta. 1975; 64(2):211-3. DOI: 10.1016/0009-8981(75)90203-x. View

17.

Volkl A, ULE G . [Trace elements in human brain. Iron concentration of 13 brain areas as a function of age]. Z Neurol. 1972; 202(4):331-8. View

18.

Lloyd K, Davidson L, Hornykiewicz O . The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther. 1975; 195(3):453-64. View